Valquiria Garcia Dinis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Valquiria Garcia Dinis has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Carla Gonçalves Schahin Saad
Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
2 shared publications - Claudia Maria Vilas Freire
Universidade Federal de Minas Gerais
2 shared publications - Fanilda Souto Barros
Instituto Fanilda Barros
2 shared publications - Joana Storino
Hospital Mater Dei, Belo Horizonte 30190-09, MG, Brazil
2 shared publications - Simone Nascimento dos Santos
Eccos Diagnóstico Cardiovascular Avançado
2 shared publications - A. O. Marinho
Fundação Hospital do Acre, Rio Branco, Brazil
1 shared publication
Latest Publications
- Open Access
- 12 February 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Impact of sex in axial spondyloarthritis: insights from the Brazilian Registry of Spondyloarthritis
Background: Sex differences in axial spondyloarthritis (axSpA) are increasingly recognized, with women often reporting higher disease burden despite similar objective inflammatory markers. This study aimed to compare clinical features, disease activity, function, quality of life, and treatment patterns between men and women with axSpA and identify sex-specific predictors of disease outcomes using data from the Brazilian Registry of Spondyloarthritis (RBE). Methods: This was a cross-sectional, observational study based on data from the RBE, a nationwide multicenter cohort including 828 patients (568 men and 260 women) from 17 referral centers across Brazil. Standardized clinical and demographic data were collected using the REDCap platform. Disease activity (ASDAS-CRP, BASDAI), physical function (BASFI), spinal mobility (BASMI), and quality of life (ASQoL) were assessed with validated instruments. Sex-stratified multivariable linear regression models were constructed to identify independent predictors of each outcome. Results: Women presented higher disease activity (median BASDAI 4.5 vs. 3.2; ASDAS-CRP 2.2 vs. 1.9), greater functional limitation (BASFI 5.0 vs. 4.0), and poorer quality of life (ASQoL 9.0 vs. 7.0) compared to men, despite similar CRP levels. Psychological distress was more frequent in women, while men had worse spinal mobility (BASMI 4.0 vs. 3.5) and higher HLA-B27 positivity. Regression models revealed that shoulder and hip pain were relevant predictors of disease activity in both sexes, but psychological factors and work activity more strongly influenced outcomes in women. Men’s disease burden was more associated with structural damage and cardiometabolic comorbidities. Conclusions: This study highlights distinct sex-related clinical patterns in axSpA. Women reported higher symptom burden, functional limitations, and reduced quality of life, largely influenced by subjective symptoms and comorbidities. Conversely, men presented greater structural impairment and different comorbidity profiles. These findings support the need for sex-informed clinical assessments and individualized management strategies in axSpA to tailor the care of these sex-specific disease trajectories, which may enhance equity and outcomes in real-world settings.
- 12 February 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessImpact of sex in axial spondyloarthritis: insights from the Brazilian Registry of Spondyloarthritis
Background: Sex differences in axial spondyloarthritis (axSpA) are increasingly recognized, with women often reporting higher disease burden despite similar objective inflammatory markers. This study aimed to compare clinical features, disease activity, function, quality of life, and treatment patterns between men and women with axSpA and identify sex-specific predictors of disease outcomes using data from the Brazilian Registry of Spondyloarthritis (RBE). Methods: This was a cross-sectional, observational study based on data from the RBE, a nationwide multicenter cohort including 828 patients (568 men and 260 women) from 17 referral centers across Brazil. Standardized clinical and demographic data were collected using the REDCap platform. Disease activity (ASDAS-CRP, BASDAI), physical function (BASFI), spinal mobility (BASMI), and quality of life (ASQoL) were assessed with validated instruments. Sex-stratified multivariable linear regression models were constructed to identify independent predictors of each outcome. Results: Women presented higher disease activity (median BASDAI 4.5 vs. 3.2; ASDAS-CRP 2.2 vs. 1.9), greater functional limitation (BASFI 5.0 vs. 4.0), and poorer quality of life (ASQoL 9.0 vs. 7.0) compared to men, despite similar CRP levels. Psychological distress was more frequent in women, while men had worse spinal mobility (BASMI 4.0 vs. 3.5) and higher HLA-B27 positivity. Regression models revealed that shoulder and hip pain were relevant predictors of disease activity in both sexes, but psychological factors and work activity more strongly influenced outcomes in women. Men’s disease burden was more associated with structural damage and cardiometabolic comorbidities. Conclusions: This study highlights distinct sex-related clinical patterns in axSpA. Women reported higher symptom burden, functional limitations, and reduced quality of life, largely influenced by subjective symptoms and comorbidities. Conversely, men presented greater structural impairment and different comorbidity profiles. These findings support the need for sex-informed clinical assessments and individualized management strategies in axSpA to tailor the care of these sex-specific disease trajectories, which may enhance equity and outcomes in real-world settings.
- Open Access
- 10 May 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 36 (2)
Valor da Ultrassonografia Vascular na Definição de Atividade Inflamatória da Arterite de Takayasu: Relatos de Casos
- 10 May 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 36 (2)
Open AccessValor da Ultrassonografia Vascular na Definição de Atividade Inflamatória da Arterite de Takayasu: Relatos de Casos
- Open Access
- 10 May 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 36 (2)
The Value of Vascular Ultrasonography in Defining Inflammatory Activity in Takayasu Arteritis: Case Reports
Introduction Takayasu arteritis (TA) is a rare large-vessel arteritis that primarily affects the aorta and its major branches. The greatest challenge is
- 10 May 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 36 (2)
Open AccessThe Value of Vascular Ultrasonography in Defining Inflammatory Activity in Takayasu Arteritis: Case Reports
Introduction Takayasu arteritis (TA) is a rare large-vessel arteritis that primarily affects the aorta and its major branches. The greatest challenge is
- 11 January 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (6) , 1747-1755
Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control
Objectives To evaluate long-term effects on gamma-globulins and autoantibodies of abatacept (ABA) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. Method Eighteen RA patients undergoing abatacept (ABA-RA) and 18 age/sex-matched patients treated with TNFi (TNFi-RA) were compared regarding clinical data, total gamma-globulins (TGG), specific subtypes (IgG, IgM, IgA), free light chains (FLC), IgM/IgG rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP3), and anti-mutated citrullinated vimentin (anti-MCV), assessed before and every 6 months, up to 24 months. Exclusion criteria: previous abatacept/rituximab or low TGG (< 0.7 g/dL). Results At baseline, female sex (78 vs. 78%), age (55 vs. 53 years), DAS28 (5.73 vs. 5.67), TGG (1.4 vs. 1.35 g/dL), IgG (1168 vs. 1079 mg/dL), IgM (107 vs. 113 mg/dL), IgA (333 vs. 322 mg/dL), kappa (342 vs. 249 mg/dL), lambda (170 vs. 150 mg/dL), IgM-RF (76 vs. 53 UI), IgG-RF (63 vs. 25 UI), anti-CCP3 (216 vs. 189 UI), and anti-MCV (202 vs. 102 UI) were comparable in ABA-RA and TNFi-RA (p > 0.05). Similar disease activity improvement was observed in both groups. In ABA-RA, significant decreases (p < 0.05) were observed in TGG (1.4 vs. 1.05 g/dL), IgG (1168 vs. 997), IgA (333 vs. 278 mg/dL), kappa (342 vs. 257 mg/dL), lambda (170 vs. 144 mg/dL), IgM-RF (76 vs. 37 UI), IgG-RF (65 vs. 24 UI), anti-CCP3 (216 vs. 183 UI), and anti-MCV (202 vs. 60 UI) at 6 months, without further decreases. In contrast, TNFi-RA showed no decrease in any of such parameters. ABA-RA also had more often transient IgG levels under the lower limit of normality (66.7% vs. 33.3%, p = 0.046). No severe infection occurred. DAS28, ESR, and CRP correlated significantly to gamma-globulins and FLC at baseline (p < 0.05), but these correlations were longitudinally lost in ABA-RA, but not in TNFi-RA. Conclusion ABA, but not TNFi, induces a safe, persistent, long-term, and non-progressive reduction in gamma-globulins and autoantibodies, including anti-MCV. This pattern is dissociated from disease activity control. Key Points • ABA induces a long-term and non-progressive reduction in gamma-globulins and FLC, which occurs regardless of disease activity control. • ABA-induced reduction in gamma-globulins and FLC promotes a dissociation of such parameters and disease activity. • The same pattern of reduction is observed in autoantibodies: IgM-RF, IgG-RF, anti-CCP3, and anti-MCV. • Low transient IgG can be observed in RA patients treated with ABA, but does not correlate to infection.
- 11 January 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (6) , 1747-1755
Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control
Objectives To evaluate long-term effects on gamma-globulins and autoantibodies of abatacept (ABA) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. Method Eighteen RA patients undergoing abatacept (ABA-RA) and 18 age/sex-matched patients treated with TNFi (TNFi-RA) were compared regarding clinical data, total gamma-globulins (TGG), specific subtypes (IgG, IgM, IgA), free light chains (FLC), IgM/IgG rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP3), and anti-mutated citrullinated vimentin (anti-MCV), assessed before and every 6 months, up to 24 months. Exclusion criteria: previous abatacept/rituximab or low TGG (< 0.7 g/dL). Results At baseline, female sex (78 vs. 78%), age (55 vs. 53 years), DAS28 (5.73 vs. 5.67), TGG (1.4 vs. 1.35 g/dL), IgG (1168 vs. 1079 mg/dL), IgM (107 vs. 113 mg/dL), IgA (333 vs. 322 mg/dL), kappa (342 vs. 249 mg/dL), lambda (170 vs. 150 mg/dL), IgM-RF (76 vs. 53 UI), IgG-RF (63 vs. 25 UI), anti-CCP3 (216 vs. 189 UI), and anti-MCV (202 vs. 102 UI) were comparable in ABA-RA and TNFi-RA (p > 0.05). Similar disease activity improvement was observed in both groups. In ABA-RA, significant decreases (p < 0.05) were observed in TGG (1.4 vs. 1.05 g/dL), IgG (1168 vs. 997), IgA (333 vs. 278 mg/dL), kappa (342 vs. 257 mg/dL), lambda (170 vs. 144 mg/dL), IgM-RF (76 vs. 37 UI), IgG-RF (65 vs. 24 UI), anti-CCP3 (216 vs. 183 UI), and anti-MCV (202 vs. 60 UI) at 6 months, without further decreases. In contrast, TNFi-RA showed no decrease in any of such parameters. ABA-RA also had more often transient IgG levels under the lower limit of normality (66.7% vs. 33.3%, p = 0.046). No severe infection occurred. DAS28, ESR, and CRP correlated significantly to gamma-globulins and FLC at baseline (p < 0.05), but these correlations were longitudinally lost in ABA-RA, but not in TNFi-RA. Conclusion ABA, but not TNFi, induces a safe, persistent, long-term, and non-progressive reduction in gamma-globulins and autoantibodies, including anti-MCV. This pattern is dissociated from disease activity control. Key Points • ABA induces a long-term and non-progressive reduction in gamma-globulins and FLC, which occurs regardless of disease activity control. • ABA-induced reduction in gamma-globulins and FLC promotes a dissociation of such parameters and disease activity. • The same pattern of reduction is observed in autoantibodies: IgM-RF, IgG-RF, anti-CCP3, and anti-MCV. • Low transient IgG can be observed in RA patients treated with ABA, but does not correlate to infection.